Acurx Pharmaceuticals, Inc.
ACXP· Nasdaq
ACXPAcurx Pharmaceuticals, Inc.
Filed May 14, 2024 · 10-Q · 44 days after period end · 0001558370-24-008130
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Net Income | -$4.38M | -$2.90M | -$2.67M | -$1.47M |
| EPS Diluted | -$0.28 | -$0.25 | -$0.26 | -$0.21 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acurx Pharmaceuticals, Inc. · CIK 1736243 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 14, 2024 · 44 d after period end
